ICC Clinical Trial - Combining Chemoradiotherapy With Sintilimab in

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT04398927` - Systemic Chemotherapy Plus PD-1 for Metastasis ICC	Phase 2
Recruiting	`NCT04769908` - Systemic Chemotherapy, Lenvatinib Plus Sintilimab for ICC With Distant Metastasis	Phase 2
Recruiting	`NCT03940378` - Treatment of Advanced Intrahepatic Cholangiocarcinoma	Phase 3
Withdrawn	`NCT04682249` - Systemic Chemotherapy, Apatinib Plus Sintilimab for Metastasis ICC	Phase 2

See also

Status

Clinical Trial

Phase

Withdrawn

NCT04398927 - Systemic Chemotherapy Plus PD-1 for Metastasis ICC

Phase 2

Recruiting

NCT04769908 - Systemic Chemotherapy, Lenvatinib Plus Sintilimab for ICC With Distant Metastasis

Phase 2

Recruiting

NCT03940378 - Treatment of Advanced Intrahepatic Cholangiocarcinoma

Phase 3

Withdrawn

NCT04682249 - Systemic Chemotherapy, Apatinib Plus Sintilimab for Metastasis ICC

Phase 2

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT06447454
Study type	Observational
Source	Shanghai Zhongshan Hospital
Contact	Shisuo Du
Phone	+86 136 2183 0381
Email	du.shisuo@zs-hospital.sh.cn
Status	Not yet recruiting
Phase
Start date	July 1, 2024
Completion date	December 31, 2028

Combining Chemoradiotherapy With Sintilimab in First-Line ICC

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms